Is There a Risk of Secondary AML in Autologous Transplant?

There's clearly an interaction between the melphoid that's used for the conditioning for these transplants and the myeloma. The benefit of a little of my maintenance seems to outweigh those few patients who get AML. Even accounting for that, it's still a better deal now whether you can change the dose or give it intermittently. So it won't have this effect or it may seem.